Hormonal therapy in cancer of the breast. XVIII. Effect of androstanediol dipropionate (5α-androstan-3α,17β-diol dipropionate) therapy on clinical course and hormonal excretion

✍ Scribed by Albert Segaloff; J. B. Weeth; E. L. Rongone; P. J. Murison

• Publisher: John Wiley and Sons
• Year: 1961
• Tongue: English
• Weight: 285 KB
• Volume: 14
• Category: Article
• ISSN: 0008-543X
• DOI: 10.1002/1097-0142(199007/08)14:4<707::aid-cncr2820140406>3.0.co;2-9

✦ Synopsis

VIDENCE of the high efficacy of testosterone E propionate against advancing breast cancer continues 1. 0 accumulate. We5 and others have previously shown that the 5a-androstanesaturated isomer of testosterone retains both its androgenicity and its clinical effectiveness. T h e further change oxidizing the 170-hydroxyl group to a ketone to produce 5a-androstan-3,17-dione4 produced a substantial decrease in both androgenicity and clinical effectiveness against advancing breast cancer. I n further investigation of this type of compound androsterone,e which differs from 5aandros tan-3,17-dione only in having the 3ketone converc.ed to a 3-hydroxyl, the compound was tested and found to have both decreased andrlogenicity and virtually n o clinical efficacy against advancing breast cancer.

Accordingly, i!j was decided to test the 5aandrostane cornpound with the 170-hydroxyl restored and with a hydroxyl group i n the 3 position instead of a ketone. Since the hydroxyl group in the 3 position can be either a or 0, and since our previous experience indicated that the compounds with the greatest androgenicity per unit weight are more effec-